Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1007/s40261-020-00917-3

http://scihub22266oqcxt.onion/10.1007/s40261-020-00917-3
suck pdf from google scholar
32337664!7183818!32337664
unlimited free pdf from europmc32337664    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32337664      Clin+Drug+Investig 2020 ; 40 (6): 511-518
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia #MMPMID32337664
  • Zhang S; Li L; Shen A; Chen Y; Qi Z
  • Clin Drug Investig 2020[Jun]; 40 (6): 511-518 PMID32337664show ga
  • Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in Wuhan, China and spread rapidly. Recent studies have found that ? 15.7% of patients develop severe pneumonia, and cytokine storm is an important factor leading to rapid disease progression. Currently, there are no specific drugs for COVID-19 and the cytokine storm it causes. IL-6 is one of the key cytokines involved in infection-induced cytokine storm. Tocilizumab, which is the IL-6 receptor antagonist, has been approved by the US FDA for the treatment of cytokine release syndrome (CRS), is expected to treat cytokine storm caused by COVID-19 and is now in clinical trials. In this paper, we will elaborate the role of cytokine storm in COVID-19, the mechanism of tocilizumab on cytokine storm and the key points of pharmaceutical care based on the actual clinical application for COVID-19 in our hospital, the latest research reports, clinical trial progress of tocilizumab, drug instruction from the US FDA, and "Diagnosis and Treatment Plan of Novel Coronavirus Pneumonia (seventh trial edition)" in China, so as to provide reference for the treatment of COVID-19.
  • |*Betacoronavirus[MESH]
  • |*Coronavirus Infections/drug therapy[MESH]
  • |*Pandemics[MESH]
  • |Adult[MESH]
  • |Aged[MESH]
  • |Aged, 80 and over[MESH]
  • |Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects/*therapeutic use[MESH]
  • |COVID-19[MESH]
  • |COVID-19 Drug Treatment[MESH]
  • |Clinical Trials as Topic[MESH]
  • |Female[MESH]
  • |Humans[MESH]
  • |Middle Aged[MESH]
  • |Pneumonia, Viral/*drug therapy/virology[MESH]
  • |Pregnancy[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box